| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Thursday’s Close |
|---|---|---|---|---|---|
| BIIB | Biogen Inc. | $334.44 | $67.37B | Downtrend |
3 Tech Stocks for Growth Investors to Buy Right Now
http://www.zacks.com/stock/news/418127/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-418127
May 22, 2019 - Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.
0
Top Research Reports for Chubb, Las Vegas Sands & Biogen
http://www.zacks.com/research-daily/417878/top-research-reports-for-chubb-las-vegas-sands-biogen?cid=CS-ZC-FT-417878
May 22, 2019 - Top Research Reports for Chubb, Las Vegas Sands & Biogen
0
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
http://www.zacks.com/stock/news/418103/biotech-stock-roundup-label-expansion-for-celgs-drugs-setback-for-imgn?cid=CS-ZC-FT-418103
May 22, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
0
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
http://www.zacks.com/stock/news/416133/celgene-gets-ec-nod-for-label-expansion-of-revlimid-imnovid?cid=CS-ZC-FT-416133
May 17, 2019 - Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
0
5 Low Price-to-Book Value Stocks for Great Returns
http://www.zacks.com/stock/news/414242/5-low-price-to-book-value-stocks-for-great-returns?cid=CS-ZC-FT-414242
May 15, 2019 - P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
0
What's in the Cards for Sunesis (SNSS) This Earnings Season?
http://www.zacks.com/stock/news/406478/whats-in-the-cards-for-sunesis-snss-this-earnings-season?cid=CS-ZC-FT-406478
May 01, 2019 - Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
0
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
http://www.zacks.com/stock/news/406790/biotech-stock-roundup-biib-vrtx-alxn-q1-earnings-top-other-pipeline-updates?cid=CS-ZC-FT-406790
May 01, 2019 - Key highlights of the past week are earnings releases by most leading biotech entities.
0
3 Tech Stocks for Growth Investors to Buy Right Now
http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-406067
Apr 30, 2019 - Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
0
Is This Highly-Anticipated Gene Therapy in Trouble?
https://www.fool.com/investing/2019/04/26/is-this-highly-anticipated-gene-therapy-in-trouble.aspx?source=iedfolrf0000001
Apr 26, 2019 - A patient death raises questions ahead of a key FDA decision next month.
0
Biogen Looks to 23 Clinical Programs for Growth
https://www.fool.com/investing/2019/04/25/biogen-looks-to-23-clinical-programs-for-growth.aspx?source=iedfolrf0000001
Apr 25, 2019 - First-quarter sales were up 11%, but future growth is less certain.
0
Page 1>